
Live Biotherapeutic Zowell Reprograms Microbiota–Lipid Crosstalk to Enhance Cisplatin Efficacy in Lung Cancer
Strategies to improve chemotherapy regimens in lung cancer remain a dire unmet clinical need. Herein, we hypothesized that manipulating the gut microbiome may improve lung cancer outcomes through alterations in immune and inflammatory mediators via the gut–lung axis. We therefore developed “Zowell”, a novel live bacterial therapeutics, and found it to reduce lung cancer growth in a mouse model when compared to both no treatment and to standard fecal microbiota transfer therapy. Furthermore, Zowell acted synergistically with the chemotherapeutic cisplatin and improved several metrics of gut health, including microbiome diversity and anti-inflammatory lipid mediators. Read more















